For the first time in a decade, the American Headache Society (AHS) has updated their recommendations for migraine treatment in the emergency room (ER). After reviewing clinical evidence, the AHS elevated two treatments to Level A, meaning providers must offer them: prochlorperazine (known by brand name Compazine) and occipital nerve blocks.

This week’s featured article explores Compazine and its role in migraine management, both inside and outside of the ER. Plus:

Wishing you a clear week ahead,